Abstract
Immunoglobulin G (IgG) molecules are glycoproteins with dual functionality. While participating in the destruction of virally infected cells or healthy tissues during autoimmune disease, IgG antibodies are also used as a therapeutic agent to suppress IgG-triggered autoimmune disease and inflammation. Research of recent years has put the IgG-associated sugar moiety in the spotlight for regulating these opposing activities. This review will focus on how certain IgG glycovariants impact different IgG-dependent effector functions and how this knowledge might be used to further improve the therapeutic effectiveness of this class of molecules.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acetylglucosamine / chemistry
-
Acetylglucosamine / immunology
-
Animals
-
Autoimmune Diseases / immunology
-
Autoimmune Diseases / therapy
-
Carbohydrate Sequence
-
Fucose / chemistry
-
Fucose / immunology
-
Galactose / chemistry
-
Galactose / immunology
-
Glycosylation
-
Humans
-
Immunoglobulin Fc Fragments / immunology*
-
Immunoglobulin Fc Fragments / therapeutic use
-
Immunoglobulin G* / immunology
-
Immunoglobulin G* / therapeutic use
-
Immunoglobulin Isotypes / chemistry
-
Immunoglobulin Isotypes / immunology*
-
Inflammation / immunology
-
Inflammation / therapy
-
Mice
-
Mice, Knockout
-
Molecular Sequence Data
-
Receptors, IgG / immunology*
-
Sialic Acids / chemistry
-
Sialic Acids / immunology
-
Virus Diseases / immunology
-
Virus Diseases / therapy
-
Virus Diseases / virology
Substances
-
Immunoglobulin Fc Fragments
-
Immunoglobulin G
-
Immunoglobulin Isotypes
-
Receptors, IgG
-
Sialic Acids
-
Fucose
-
Acetylglucosamine
-
Galactose